Dexcom’s New Over-the-Counter Glucose Monitor Widens Access

Original Article: https://www.medtechdive.com/news/dexcom-over-the-counter-cgm/709615

Expanding Use of Dexcom’s CGM

The FDA recently approved Dexcom’s continuous glucose monitor (CGM) for over-the-counter (OTC) sale. This means people, including those without diabetes and those not on insulin, can purchase it without a prescription. Originally targeted at people with type 2 diabetes (T2D) not using insulin, the FDA broadened its approval to most adults not on insulin including those with prediabetes and also people interested in finding out how their food choices and physical activity affect their glucose levels.

Growth and Features of Dexcom’s Stelo

Dexcom’s Stelo, based on the G7 CGM, features a redesigned app tailored for T2D adultss not using insulin. It offers a 15-day wear time and is priced similar to other existing CGMs. 

Implications for Competitors and Future Devices

The FDA’s decision sets a precedent for competitors, emphasizing the importance of accuracy and clear labeling. While Dexcom prepares for Stelo’s launch, competitors like Abbott are also eyeing broader access. This move marks a significant step in making CGM technology more accessible to a wider population.